📌 Key Takeaways
- A November 2025 network meta-analysis from Hamburg University Medical Center
compared 10 device-based treatments for rosacea across 25 RCTs —
the first study of its kind to do so on a unified evidence base. - RF microneedling significantly outperformed pulsed dye laser (PDL)
for both erythema reduction (MD –1.44) and patient satisfaction (MD –1.32). - For telangiectasia (visible broken capillaries),
oxymetazoline + PDL combination showed the most promise (MD –0.58). - The right device depends on your specific symptom profile —
not a one-size-fits-all answer.
For years, patients with persistent facial redness have faced a frustrating reality:
plenty of device options, but almost no head-to-head evidence to guide the choice.
In November 2025, researchers at Hamburg University Medical Center published
the first systematic review and network meta-analysis (NMA)
to compare laser and energy-based devices for rosacea on a common evidence platform.
The findings challenge some long-held assumptions —
and offer a clearer framework for symptom-specific treatment decisions.
INDEX
What Is Rosacea — and How Is It Different from General Facial Redness?
Rosacea is a chronic inflammatory skin condition primarily affecting the central face
(cheeks, nose, forehead, chin).
Core features include: persistent erythema (redness), transient flushing,
telangiectasia (visible dilated capillaries), inflammatory papules and pustules,
and in some cases phymatous changes (tissue thickening, especially on the nose).
Prevalence estimates range from under 1% to 22% depending on population,
diagnostic criteria, and region.
The condition is strongly associated with reduced quality of life
and lower self-esteem due to its visible nature.
Key distinction: “Facial redness” is a lay term covering many causes —
sensitive skin, eczema, contact reactions, alcohol flush.
Rosacea is a specific clinical diagnosis requiring evaluation by a dermatologist
or aesthetic medicine physician.
Device-based treatments target the symptoms that skincare alone cannot adequately address:
persistent vascular redness and visible capillaries.
This study focused precisely on that question —
which devices work best, and for which symptoms.
Why This Study Is a First: Understanding Network Meta-Analysis
An NMA pools data from multiple randomized controlled trials (RCTs)
and enables indirect comparisons between treatments
that were never directly tested against each other.
If Trial A compares Treatment 1 vs. Treatment 2,
and Trial B compares Treatment 2 vs. Treatment 3,
an NMA can estimate the relative effect of Treatment 1 vs. Treatment 3.
This makes it possible to rank multiple therapies simultaneously —
something no single RCT can achieve.
Prior to this study, evidence for rosacea device treatments existed in silos.
Individual trials showed PDL works. Others showed IPL is effective.
Others supported RF microneedling.
But no study had placed all 10 treatment approaches on the same comparative platform.
Nguyen et al. qualitatively reviewed 25 RCTs
and incorporated a subset into three sub-networks for quantitative NMA,
enabling the first cross-treatment ranking by symptom outcome.
Results by Symptom: The Right Device Depends on What You’re Treating
The study evaluated outcomes across three primary axes.
The findings differ meaningfully depending on the symptom in question.
RF microneedling demonstrated a statistically significant advantage over PDL
in reducing erythema — the most common and visible symptom of rosacea.
PDL (pulsed dye laser) has long been the standard of care for vascular rosacea,
making this finding clinically notable.
Patient-reported satisfaction mirrored the erythema findings.
RF microneedling ranked first here as well —
a result that may partly reflect its more favorable downtime profile
compared to PDL, which commonly causes post-treatment purpura (bruising).
For patients whose primary concern is visible dilated capillaries —
rather than diffuse redness — the picture shifts.
Oxymetazoline (a topical vasoconstrictor) combined with PDL
showed the strongest signal for telangiectasia reduction.
RF microneedling, which ranked first for erythema and satisfaction,
did not lead this sub-network.
— The number of included studies per sub-network was limited;
comparisons involve indirect estimates.
— Device parameters, protocols, and outcome measures varied across trials.
— Adverse event and discontinuation rates did not differ significantly between treatments.
— Subtype-specific conclusions (e.g., erythematotelangiectatic vs. papulopustular rosacea)
cannot be drawn from this analysis alone.
Why Would RF Microneedling Reduce Redness? The Mechanism Explained
The intuitive assumption is that lasers treat redness — not needles.
Understanding why RF microneedling performs well for erythema
requires distinguishing between two fundamentally different mechanisms.
Targets and destroys abnormal vasculature directly.
Highly effective for visible vessels — but associated with post-treatment purpura
and a recovery period of several days to weeks.
Stimulates collagen remodeling and — critically —
is thought to modulate the chronic inflammatory environment
underlying rosacea by influencing cytokine signaling and barrier function.
Rather than destroying vessels, it may address the inflammatory substrate
that drives persistent redness.
Note: this mechanistic explanation is based on existing literature,
not a direct finding of the Nguyen et al. study.
This distinction may help explain the patient satisfaction gap.
PDL’s direct vascular targeting is powerful but comes with visible downtime.
RF microneedling’s approach — working through dermal remodeling
and inflammatory modulation — tends to involve less visible recovery,
which may contribute to higher reported satisfaction.
Facial redness is not a single condition.
Persistent diffuse erythema, episodic flushing, visible capillaries, and nasal redness
each represent different pathophysiological patterns.
What this study gives us is a starting framework:
RF microneedling for generalized redness,
oxymetazoline + PDL for visible telangiectasia —
but the clinical picture always requires individual assessment.
Rosacea is managed, not cured.
Device treatment is one layer of a longer strategy
that must include daily sun protection, trigger avoidance
(alcohol, spicy food, heat, stress), and consistent skincare.
At NERO, we believe the most important question isn’t just
“which device” — it’s “how will this be managed over time.”
Summary
- Nguyen et al. (JDDG, published November 21, 2025) conducted the first systematic review
and NMA comparing 10 device-based treatments for rosacea,
analyzing 321 observations across 3 sub-networks of RCT data. - RF microneedling significantly outperformed PDL
for erythema reduction (MD –1.44) and patient satisfaction (MD –1.32).
Adverse event rates did not differ significantly across treatments. - For telangiectasia, oxymetazoline + PDL combination
showed the strongest signal (MD –0.58),
highlighting that optimal treatment varies by symptom type. - Study limitations include heterogeneous protocols across trials
and the indirect nature of NMA comparisons.
Subtype-specific treatment decisions require consultation
with a dermatologist or aesthetic medicine physician.
Frequently Asked Questions
Facial redness has multiple possible causes beyond rosacea,
including seborrheic dermatitis, atopic dermatitis, contact dermatitis, and sensitive skin reactions.
Receiving laser or energy-based treatment without a confirmed diagnosis
can worsen certain conditions.
Establishing the correct diagnosis — and rosacea subtype if applicable —
is the essential first step before any device treatment.
Sylfirm X, Secret RF, Morpheus8, Profound, and others all fall within this category —
but differ in needle type (insulated vs. non-insulated),
RF frequency, depth of energy delivery, and cooling mechanisms.
These differences affect which tissue layers are targeted and which indications each device suits best.
The Nguyen et al. study evaluated RF microneedling as a class;
it does not establish superiority of any specific device.
Ask your provider which device they use and why it suits your specific concern.
Common triggers include alcohol, spicy foods, hot beverages, sun exposure,
stress, intense exercise, and rapid temperature changes.
Individual trigger sensitivity varies significantly —
keeping a trigger diary and sharing it with your physician is a practical strategy.
Daily broad-spectrum sunscreen use (mineral formulations with zinc oxide or titanium dioxide
tend to be better tolerated by reactive skin) is also consistently recommended.
Source: Nguyen L, Sorbe C, Seeber N, Schneider SW, Herberger K. “Laser and energy-based devices for treating rosacea — a systematic review and network meta-analysis.” Journal of the German Society of Dermatology (JDDG). 2026 Jan;24(1):24–32. Epub 2025 Nov 21. doi:10.1111/ddg.15961. PMID: 41273013. PMC: PMC12800891. Wiley / PMC12800891
